Answers are grounded in this paper and cite their sources.
alterations in Phase I clinical trials in adults. Entrectinib's activity against both ALK and TRK proteins suggests a possible role in NB treatment, and it is currently under investigation in both pediatric and adult oncology patients.
No takes yet. Share an insight, caveat, or question.
Pacenta et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: